What's Happening?
Bruker Corporation has introduced iNTApharma, a new label-free platform designed for the characterization of nanoparticles, particularly in the development and quality control of mRNA drugs and gene therapies.
The system, unveiled at the SLAS 2026 conference in Boston, offers rapid, native-state size and concentration measurements with single-particle sensitivity. This technology is crucial for analyzing viral vectors, lipid nanoparticles, and other nanoscale bioparticles in their native aqueous media without the need for labeling or chemical modifications. The iNTApharma platform is optimized for bioparticles ranging from 50 to 300 nanometers and supports the analysis of heterogeneous samples, including the resolution of subpopulations within mixtures. It incorporates advanced interferometric scattering detection methods, making it a valuable tool for researchers and developers in biopharma and translational research.
Why It's Important?
The introduction of iNTApharma is significant as it addresses the growing demand for precise nanoparticle characterization in the rapidly expanding fields of mRNA drug development and gene therapy. As these areas experience double-digit growth rates, the need for reliable and high-precision tools becomes critical. The platform's ability to provide native-state, quantitative analysis without labeling enhances the accuracy and efficiency of research and quality control processes. This advancement supports the development of more effective therapies and could accelerate the pace of innovation in biopharmaceuticals, ultimately benefiting patients through improved treatment options.
What's Next?
Bruker plans to place initial iNTApharma systems with early-access partners in the first half of 2026 to validate workflows under real-world conditions. Broader commercial availability is expected in the second half of 2026. This rollout will likely attract interest from biopharmaceutical companies and research institutions looking to enhance their nanoparticle analysis capabilities. As the platform gains traction, it may lead to further advancements in the development of mRNA therapies and gene therapies, potentially influencing industry standards and practices.
